NHC Key Laboratory of Carcinogenesis and Hunan Key Laboratory of Translational Radiation Oncology, Hunan Cancer Hospital and The Affiliated Cancer Hospital, Xiangya School of Medicine, Central South University, Changsha, Hunan, China.
Key Laboratory of Carcinogenesis and Cancer Invasion of the Chinese Ministry of Education, Cancer Research Institute, Central South University, Changsha, Hunan, China.
Mol Cancer. 2021 Jan 4;20(1):7. doi: 10.1186/s12943-020-01288-1.
Vasculogenic mimicry (VM) is a recently discovered angiogenetic process found in many malignant tumors, and is different from the traditional angiogenetic process involving vascular endothelium. It involves the formation of microvascular channels composed of tumor cells; therefore, VM is considered a new model for the formation of new blood vessels in aggressive tumors, and can provide blood supply for tumor growth. Many studies have pointed out that in recent years, some clinical treatments against angiogenesis have not been satisfactory possibly due to the activation of VM. Although the mechanisms underlying VM have not been fully elucidated, increasing research on the soil "microenvironment" for tumor growth suggests that the initial hypoxic environment in solid tumors is inseparable from VM.
In this review, we describe that the stemness and differentiation potential of cancer stem cells are enhanced under hypoxic microenvironments, through hypoxia-induced epithelial-endothelial transition (EET) and extracellular matrix (ECM) remodeling to form the specific mechanism of vasculogenic mimicry; we also summarized some of the current drugs targeting VM through these processes, suggesting a new reference for the clinical treatment of tumor angiogenesis.
Overall, the use of VM inhibitors in combination with conventional anti-angiogenesis treatments is a promising strategy for improving the effectiveness of targeted angiogenesis treatments; further, considering the importance of hypoxia in tumor invasion and metastasis, drugs targeting the hypoxia signaling pathway seem to achieve good results.
血管生成拟态(VM)是一种最近发现的血管生成过程,存在于许多恶性肿瘤中,与涉及血管内皮的传统血管生成过程不同。它涉及由肿瘤细胞组成的微血管通道的形成;因此,VM 被认为是侵袭性肿瘤中新血管形成的新模型,并可为肿瘤生长提供血液供应。许多研究指出,近年来,一些针对血管生成的临床治疗并不令人满意,可能是由于 VM 的激活。尽管 VM 的机制尚未完全阐明,但越来越多的关于肿瘤生长“土壤微环境”的研究表明,实体瘤中最初的缺氧环境与 VM 密不可分。
在这篇综述中,我们描述了在缺氧微环境下,肿瘤干细胞的干性和分化潜能增强,通过缺氧诱导的上皮-内皮转化(EET)和细胞外基质(ECM)重塑形成血管生成拟态的特定机制;我们还总结了一些目前通过这些过程靶向 VM 的药物,为肿瘤血管生成的临床治疗提供了新的参考。
总的来说,使用 VM 抑制剂与常规抗血管生成治疗相结合是提高靶向血管生成治疗效果的有前途的策略;此外,考虑到缺氧在肿瘤侵袭和转移中的重要性,靶向缺氧信号通路的药物似乎会取得良好的效果。